Clinical trials
Malignant Solid Neoplasm clinical trials
Below are recruiting malignant solid neoplasm clinical trials, each written for real people, not researchers. We’re tracking 296 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07664579Recruiting
Couples coping together against cancer support program
This trial tests a supportive care program for couples facing cancer. It helps you and your partner work together to manage the challenges of a cancer diagnosis.
Duarte, CaliforniaAges 18 years+ - NCT05880667RecruitingPhase 1
Adaptive focused radiation for belly and pelvic cancer spread
This Phase 1 study tests an “adaptive” form of focused radiation (SBRT) for cancers that have spread in the abdomen or pelvis. It aims to treat metastatic tumor spots safely while adjusting the plan as needed during treatment.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07741435Recruiting
Simple blood, urine, and saliva test to find cancer early
This study tests a new way to find cancer by looking at DNA in blood, urine, and saliva. It may help detect cancer earlier and monitor how well treatment works.
Bogotá, Bogota D.C.Ages 18 years+ - NCT06577987RecruitingPhase 1
Study of CID-078 for advanced solid tumors
This trial tests an experimental drug called CID-078 for people with advanced solid tumors that have stopped responding to other treatments. It aims to find the right dose and see if the drug can shrink tumors.
Sarasota, FloridaAges 12 years+ - NCT07631793RecruitingPhase 1
YKYY031 injection for advanced solid tumors with specific genetic mutations
This early-stage trial tests a new cancer treatment (YKYY031) given by injection for advanced colorectal or pancreatic cancer that has stopped responding to standard treatments. The drug is designed to target specific genetic changes (mutations) found in some tumors, and your immune system must match a particular genetic marker (HLA-A*11:01) for the drug to work.
Beijing, Beijing MunicipalityAges 18–75 - NCT07660432RecruitingPhase 1
Testing SIM0689 for advanced solid tumors
This study tests a new drug called SIM0689 for people with advanced solid tumors that have not responded to other treatments. The goal is to see if the drug is safe and effective, and researchers will look at tumor samples to understand which patients might benefit most.
Fuzhou, FujianAges 18 years+ - NCT06506643RecruitingPhase 1/Phase 2
Study of KLS-1 for solid tumors and CLL
This trial tests a new drug called KLS-1 for people with solid tumors (like melanoma, pancreatic, or prostate cancer) or chronic lymphocytic leukemia (CLL) that is no longer responding to standard treatments. The goal is to see if KLS-1 is safe and can shrink tumors or slow the cancer.
KropyvnytskyiAges 18 years+ - NCT05918445RecruitingPhase 1/Phase 2
PM8002 for advanced solid tumors that have stopped responding
This Phase 1/2 study tests PM8002 in people with advanced solid cancers to see if it can work and is safe. It may help if your cancer has measurable disease and you have not fully recovered from side effects of prior treatment.
BaojiAges 18–75 - NCT06051760RecruitingPhase 1
NV-001 for advanced solid tumors after standard treatments
This trial tests a new drug called NV-001 for people with advanced solid tumors that are no longer responding to standard treatments. It aims to see if the drug is safe and can help shrink or slow tumor growth.
Beijing, Beijing MunicipalityAges 18–75 - NCT07244835RecruitingPhase 1
A study of DEG6498 for advanced solid tumors
This trial tests a new drug, DEG6498, for people with advanced solid tumors that have not responded to other treatments. It may be an option if your cancer has a BRAF mutation or is a type of liver cancer called HCC.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07610941RecruitingPhase 1
Testing a new cancer drug alone and combined with others
This early-stage trial tests a new experimental drug (MST-0312) in people with solid tumors like lung cancer, melanoma, bladder cancer, colorectal cancer, or triple-negative breast cancer. The goal is to find safe doses and see how well it works, either by itself or paired with other treatments.
BarcelonaAges 18 years+ - NCT07465523Recruiting
New Doppler ultrasound for breast mass evaluation
This trial tests a new Doppler ultrasound method to evaluate solid breast masses. It may help doctors get more information about your mass if you have a biopsy result.
Karaman, Lütfen Seçiniz.Ages 18 years+ - NCT05592626RecruitingPhase 1/Phase 2
T cell activator STAR0602 for advanced solid tumors
This study tests an experimental drug called STAR0602 that aims to boost your immune system's T cells to fight advanced solid tumors. It's for patients whose cancer has not responded to standard treatments or for whom such treatments are not suitable.
Sacramento, CaliforniaAges 18 years+ - NCT05461664Recruiting
Avapritinib for advanced GIST without PDGFRA exon 18 changes
This trial studies avapritinib, a targeted medicine, for people with advanced or returning gastrointestinal stromal tumors (GIST) whose tumor does not have PDGFRA exon 18 mutations. It aims to see how well the drug can shrink tumors or control the disease.
GuangzhouAges 18 years+ - NCT05464875Recruiting
Testing avapritinib for advanced GI stromal tumors
This study looks at how well avapritinib works and how safe it is for people with metastatic or unresectable gastrointestinal stromal tumors (GIST). It focuses on whether the tumor has certain marker and gene features and whether you can tolerate related medications.
GuangzhouAges 18 years+ - NCT03023202Recruiting
Study your tumor’s genetic results in a review board
This study collects genetic testing results from people with cancer and shares them with a specialized tumor review team. It may help future care planning by improving how tumor genetics are interpreted.
Madison, WisconsinAges 18 years+ - NCT07209111RecruitingPhase 2
Testing Calderasib for advanced solid tumors with KRAS G12C mutation
This trial tests a new drug, Calderasib (MK-1084), for people with advanced solid tumors that have a specific KRAS G12C mutation and aren't getting better with standard treatments. The goal is to see if the drug can help shrink or control the cancer.
Baltimore, MarylandAges 18 years+ - NCT07247110RecruitingPhase 1
Study of MK-4716 for people with certain solid tumors
This trial tests a new drug, MK-4716, alone or with cetuximab or pembrolizumab, for people with advanced solid tumors that have a specific KRAS gene change. It aims to see if the drug can shrink tumors or slow their growth.
New Brunswick, New JerseyAges 18 years+ - NCT07600749RecruitingPhase 1
MK-4884 study for advanced solid tumors
This early-stage study tests a new drug called MK-4884 in patients with advanced cancers that have spread. The trial includes colorectal, kidney, lung, and bile duct cancers, and aims to find the right dose and see if the drug helps shrink tumors.
San Antonio, TexasAges 18 years+ - NCT07483658Recruiting
Salvage pelvic radiotherapy: 20 vs 25 sessions for recurring prostate cancer
This trial compares two schedules of pelvic radiotherapy for men whose prostate cancer has returned after surgery. Both schedules aim to control the cancer with fewer visits for one of them.
Gatineau, QuebecAges 18 years+ - NCT05733156Recruiting
Low-dose radiation to trigger whole-body cancer effects
This trial tests whether giving a low dose of radiation to one spot can help shrink cancer in other, untreated areas (the “abscopal effect”) in people with multiple metastases. It may help by boosting the body’s response to stereotactic body radiotherapy (focused high-dose radiation) for tumors outside the brain.
SeoulAges 19 years+ - NCT03366116RecruitingPhase 1
Testing an epigenetic drug for advanced solid tumors
This early-phase study tests Aza-TdC in adults with advanced solid cancers that have grown despite standard treatment, or for which no standard options exist. The goal is to see if the drug can be given safely and start to show signs of benefit against tumors.
Bethesda, MarylandAges 18–120 - NCT07102004RecruitingPhase 1/Phase 2
Testing a new drug for advanced solid tumors
This trial tests an experimental drug for people with advanced solid tumors, including small cell lung cancer, that have stopped responding to standard treatments. The goal is to find out if the drug is safe and effective.
BeijingAges 18 years+ - NCT07023640Recruiting
Imaging test for tumors using a new tracer agent
This trial tests a new imaging method (68Ga-DOTA-mPNE PET/CT) to see if it can help detect cancers. It's for people who haven't had chemotherapy or radiation yet and will have a biopsy or surgery.
Beijing, Beijing MunicipalityAges 18–70
Hear when a new Malignant Solid Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for malignant solid neoplasm?
- Yes. Clin2 currently lists 296 recruiting malignant solid neoplasm studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a malignant solid neoplasm trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a malignant solid neoplasm trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.